Dr. Sarah Goldberg

Doctor Overview

Dr. Sarah Goldberg is a thoracic oncologist at the Yale Cancer Center, where she treats cancer patients. She holds a number of leadership roles there. She is:

• Associate Program Director for the Medical Oncology-Hematology Fellowship
• Chief of Thoracic Oncology
• Research Director for the Center for Thoracic Cancers

Dr. Goldberg also teaches as an associate professor at the Yale School of Medicine and conducts clinical research on lung cancer.

Dr. Goldberg earned her medical degree at Mount Sinai School of Medicine. She did her residency at Massachusetts General Hospital and completed her fellowship at the Dana-Farber Cancer Institute. She also holds a Master of Public Health (MPH) from the Harvard School of Public Health.

Dr. Goldberg frequently sees patients at the Smilow Cancer Hospital Care Center – North Haven location. Dr. Goldberg is a clinician with a special focus on cancers of the lungs and chest. These include illnesses such as lung cancer, mesothelioma and thymoma.

She also conducts clinical trials, clinical and translational research and has published numerous studies and articles. Dr. Goldberg’s primary research focus is novel treatment strategies for certain types of lung cancer, including immunotherapy treatments like checkpoint inhibitors. Dr. Goldberg has also presented on mesothelioma diagnosis and traditional and emerging treatments for pleural mesothelioma.

Doctor Fast Facts

Main Specialty: Thoracic Oncology

Other Interests & Specialties: Non-small cell lung cancer, immunotherapy, thoracic neoplasms and biomarkers.

Certifications, Awards & Accolades: Yale Cancer Center Award for Teaching Excellence 2023

Education & Experience:

• Medical Degree from Mount Sinai School of Medicine
• Master’s Degree in Public Health from Harvard School of Public Health
• Residency at Massachusetts General Hospital
• Fellowship at Dana-Farber Cancer Institute

Publications

The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer. The Lancet. March 2023;401(10378):706-707. doi: 10.1016/S0140-6736(23)00288-X

Cancer of the Lung. Holland-Frei Cancer Medicine. October 2022. doi: 10.2002/9781119000822.hfcm085.pub2

Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open. August 2022;5(8):e2224478. doi: 10.1001/jamanetworkopen.2022.24478

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for Immunotherapy of Cancer. May 2022;10(5):e003956. doi: 10.1136/jitc-2021-003956

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology. June 2020;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006

Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer? Cancer. December 2018;124(24):4592-4596. doi: 10.1002/cncr.31681

Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy. September 2018;10(12):1023-1025. doi: 10.2217/imt-2018-0084